Tomoko Ichiki1, Brenda K Huntley2, S Jeson Sangaralingham2, John C Burnett2. 1. Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: ichiki.tomoko@mayo.edu. 2. Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Abstract
OBJECTIVES: The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP). BACKGROUND: ProANP is produced in the atria and processed to ANP and activates the guanylyl cyclase receptor-A (GC-A) and its second messenger, cyclic guanosine monophosphate (cGMP). ProANP is found in the human circulation, but its bioavailability is undefined. METHODS: The in vivo actions of proANP compared with ANP, BNP, and placebo were investigated in normal canines (667 pmol/kg, n = 5/group). cGMP activation in human embryonic kidney 293 cells expressing GC-A or guanylyl cyclase receptor-B was also determined. ProANP processing and degradation were observed in serum from normal subjects (n = 13) and patients with heart failure (n = 14) ex vivo. RESULTS: ProANP had greater diuretic and natriuretic properties, with more sustained renal tubular actions, compared with ANP and BNP in vivo in normal canines, including marked renal vasodilation not observed with ANP or BNP. ProANP also resulted in greater and more prolonged cardiac unloading than ANP but much less hypotensive effects than BNP. ProANP stimulated cGMP generation by GC-A as much as ANP. ProANP was processed to ANP in serum from normal control subjects and patients with heart failure ex vivo. CONCLUSIONS: ProANP represents a novel activator of GC-A with enhanced diuretic, natriuretic, and renal vasodilating properties, and it may represent a key circulating natriuretic peptide in cardiorenal and blood pressure homeostasis. These results support the concepts that proANP may be a potential innovative therapeutic beyond ANP or BNP for cardiorenal diseases, including heart failure.
OBJECTIVES: The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP). BACKGROUND:ProANP is produced in the atria and processed to ANP and activates the guanylyl cyclase receptor-A (GC-A) and its second messenger, cyclic guanosine monophosphate (cGMP). ProANP is found in the human circulation, but its bioavailability is undefined. METHODS: The in vivo actions of proANP compared with ANP, BNP, and placebo were investigated in normal canines (667 pmol/kg, n = 5/group). cGMP activation in humanembryonic kidney 293 cells expressing GC-A or guanylyl cyclase receptor-B was also determined. ProANP processing and degradation were observed in serum from normal subjects (n = 13) and patients with heart failure (n = 14) ex vivo. RESULTS:ProANP had greater diuretic and natriuretic properties, with more sustained renal tubular actions, compared with ANP and BNP in vivo in normal canines, including marked renal vasodilation not observed with ANP or BNP. ProANP also resulted in greater and more prolonged cardiac unloading than ANP but much less hypotensive effects than BNP. ProANP stimulated cGMP generation by GC-A as much as ANP. ProANP was processed to ANP in serum from normal control subjects and patients with heart failure ex vivo. CONCLUSIONS:ProANP represents a novel activator of GC-A with enhanced diuretic, natriuretic, and renal vasodilating properties, and it may represent a key circulating natriuretic peptide in cardiorenal and blood pressure homeostasis. These results support the concepts that proANP may be a potential innovative therapeutic beyond ANP or BNP for cardiorenal diseases, including heart failure.
Authors: Neal L Weintraub; Sean P Collins; Peter S Pang; Phillip D Levy; Allen S Anderson; Cynthia Arslanian-Engoren; W Brian Gibler; James K McCord; Mark B Parshall; Gary S Francis; Mihai Gheorghiade Journal: Circulation Date: 2010-10-11 Impact factor: 29.690
Authors: Tomoko Ichiki; Brenda K Huntley; Denise M Heublein; Sharon M Sandberg; Paul M McKie; Fernando L Martin; Michihisa Jougasaki; John C Burnett Journal: Clin Chem Date: 2010-11-12 Impact factor: 8.327
Authors: C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Alexander G Semenov; Karina R Seferian; Natalia N Tamm; Marina M Artem'eva; Alexander B Postnikov; Anastasiya V Bereznikova; Andrey N Kara; Natalia A Medvedeva; Alexey G Katrukha Journal: Clin Chem Date: 2011-04-07 Impact factor: 8.327
Authors: Fernando L Martin; S Jeson Sangaralingham; Brenda K Huntley; Paul M McKie; Tomoko Ichiki; Horng H Chen; Josef Korinek; Gerald E Harders; John C Burnett Journal: PLoS One Date: 2012-12-18 Impact factor: 3.240
Authors: Yang Chen; Ye Zheng; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; Horng H Chen; Tomoko Ichiki; John C Burnett; S Jeson Sangaralingham Journal: J Mol Cell Cardiol Date: 2019-04-04 Impact factor: 5.000
Authors: Laura M G Meems; Ingrid A Andersen; Shuchong Pan; Gail Harty; Yang Chen; Ye Zheng; Gerald E Harders; Tomoki Ichiki; Denise M Heublein; Seethalakshmi R Iyer; S Jeson Sangaralingham; Daniel J McCormick; John C Burnett Journal: Hypertension Date: 2019-04 Impact factor: 9.897
Authors: Matthew Hoffman; Ioannis D Kyriazis; Alexandra Dimitriou; Santosh K Mishra; Walter J Koch; Konstantinos Drosatos Journal: JCI Insight Date: 2020-04-23